The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 06, 2025

Filed:

Nov. 03, 2023
Applicant:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Inventors:

Thazha P. Prakash, Carlsbad, CA (US);

Punit P. Seth, Carlsbad, CA (US);

Eric E. Swayze, Encinitas, CA (US);

Mark J. Graham, San Clemente, CA (US);

Assignee:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2005.12); A61K 31/7088 (2005.12); A61K 31/713 (2005.12); A61K 47/54 (2016.12); C12N 15/11 (2005.12); C12N 15/113 (2009.12);
U.S. Cl.
CPC ...
C12N 15/113 (2012.12); A61K 31/7088 (2012.12); A61K 31/713 (2012.12); A61K 47/549 (2017.07); C07H 21/04 (2012.12); C12N 15/111 (2012.12); C12N 2310/11 (2012.12); C12N 2310/113 (2012.12); C12N 2310/17 (2012.12); C12N 2310/31 (2012.12); C12N 2310/315 (2012.12); C12N 2310/321 (2012.12); C12N 2310/322 (2012.12); C12N 2310/3231 (2012.12); C12N 2310/3341 (2012.12); C12N 2310/341 (2012.12); C12N 2310/346 (2012.12); C12N 2310/351 (2012.12); C12N 2310/3511 (2012.12); C12N 2310/3513 (2012.12); C12N 2310/3515 (2012.12); C12N 2310/3525 (2012.12); C12N 2310/353 (2012.12); C12N 2320/32 (2012.12);
Abstract

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.


Find Patent Forward Citations

Loading…